Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
less,21077681,IC₅₀,Cellular assays confirmed that compound 78 was the most potent against two hematologic and some solid tumor cells with IC₅₀ values less than 1 μM.,"Synthesis, in vitro and in vivo biological evaluation, and comprehensive understanding of structure-activity relationships of dipeptidyl boronic acid proteasome inhibitors constructed from β-amino acids. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21077681/),μM,1,7848,DB00188,Bortezomib
,25248382,MTD,The MTD was established as 1.3 mg/m(2) for bortezomib and 40 mg/m(2) for alvocidib.,"Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248382/),[mg] / [m(2],1.3,15942,DB00188,Bortezomib
,25248382,MTD,The MTD was established as 1.3 mg/m(2) for bortezomib and 40 mg/m(2) for alvocidib.,"Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248382/),[mg] / [m(2],40,15943,DB00188,Bortezomib
,25248382,total response rate,Three complete remissions (8%) and 10 partial remissions (26%) were observed for a total response rate of 33%.,"Phase I trial of bortezomib (PS-341; NSC 681239) and ""nonhybrid"" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25248382/),%,33,15944,DB00188,Bortezomib
,24486861,extraction recovery,"Pomalidomide was stable in plasma through 4 freeze-thaw cycles (<12% change), in plasma at room temperature for up to 2h for samples not pre-stabilized with 0.1% HCl and up to 8h in samples pre-stabilized with 0.1% HCl, 24h post-preparation at 4°C (<2% change), and showed excellent extraction recovery (∼90%).",A sensitive and robust HPLC assay with fluorescence detection for the quantification of pomalidomide in human plasma for pharmacokinetic analyses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24486861/),%,∼90,20504,DB00188,Bortezomib
,24392952,ultrafiltration flow rates,"During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5 mL/min, respectively) comparing a highly permeable HCO dialyzer (Theralite, 2.1 m(2) ) to a high-flux dialyzer (PFX; 2.1 m(2) ), ultrafiltered volume was replaced by saline containing 30 g/L urea.",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],250,25288,DB00188,Bortezomib
,24392952,ultrafiltration flow rates,"During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5 mL/min, respectively) comparing a highly permeable HCO dialyzer (Theralite, 2.1 m(2) ) to a high-flux dialyzer (PFX; 2.1 m(2) ), ultrafiltered volume was replaced by saline containing 30 g/L urea.",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],500,25289,DB00188,Bortezomib
,24392952,ultrafiltration flow rates,"During in vitro hemodialysis with human blood (blood, dialysate, and ultrafiltration flow rates 250, 500 and 5 mL/min, respectively) comparing a highly permeable HCO dialyzer (Theralite, 2.1 m(2) ) to a high-flux dialyzer (PFX; 2.1 m(2) ), ultrafiltered volume was replaced by saline containing 30 g/L urea.",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],5,25290,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,40,25291,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],80,25292,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],65,25293,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,70,25294,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],40,25295,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],33,25296,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,65,25297,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],47,25298,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],38,25299,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],125,25300,DB00188,Bortezomib
,24392952,Plasma K,"Plasma K values of HCO and PFX for THA, BOR, and DEX were about 40% (80 ± 7 vs. 65 ± 6 mL/min; P < 0.05), 70% (40 ± 8 vs. 33 ± 4 mL/min; P < 0.05), and 65% (47 ± 11 vs. 38 ± 7 mL/min; P < 0.05), respectively-lower (P < 0.0001) compared with urea (125 ± 7 vs. 122 ± 5 mL/min).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),[ml] / [min],122,25301,DB00188,Bortezomib
,24392952,PBF,"Compared with BOR and DEX (minimum 72 and 56%, respectively), the PBF of THA (37%) was significantly lower (P < 0.001).",Clearance of drugs for multiple myeloma therapy during in vitro high-cutoff hemodialysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24392952/),%,37,25302,DB00188,Bortezomib
,28626947,Cmax (maximum observed plasma concentration),"Mean (SD) Cmax (maximum observed plasma concentration) on day 11 was 266 (77.5) ng/mL, approximately 60% higher compared with non-Asian patients receiving a similar bortezomib regimen but with overlapping ranges.",Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626947/),[ng] / [ml],266,26362,DB00188,Bortezomib
,28626947,AUClast,"Overall, bortezomib exposure (AUC) in Taiwanese patients (AUClast [SD]: 230 [147] ng·h/mL) with twice weekly intravenous administration was comparable with non-Asian population (AUClast [SD]: 241 [82] ng·h/mL).",Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626947/),[h·ng] / [ml],230,26363,DB00188,Bortezomib
,28626947,AUClast,"Overall, bortezomib exposure (AUC) in Taiwanese patients (AUClast [SD]: 230 [147] ng·h/mL) with twice weekly intravenous administration was comparable with non-Asian population (AUClast [SD]: 241 [82] ng·h/mL).",Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28626947/),[h·ng] / [ml],241,26364,DB00188,Bortezomib
,20158184,IC(50),"The IC(50) value of its pure enantiomer 4q was 9.6 nM, 36-fold more active than its isomer 4p and as active as the marketed bortezomib in inhibiting human 20S proteasome.","Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20158184/),nM,9.6,27866,DB00188,Bortezomib
less,20158184,IC(50),This candidate also showed good activities with IC(50) values nearly less than 5 microM against several human solid and hematologic tumor cell lines.,"Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20158184/),μM,5,27867,DB00188,Bortezomib
,18454159,Overall patient response rate,Overall patient response rate was 29%.,Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18454159/),%,29,28241,DB00188,Bortezomib
,18454159,time to progression,Median time to progression was 5.4 months.,Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18454159/),month,5.4,28242,DB00188,Bortezomib
,18454159,time to response,"In patients with confirmed response, median time to response was 1.3 months and median duration of response was 3.2 months.",Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18454159/),month,1.3,28243,DB00188,Bortezomib
,18454159,duration of response,"In patients with confirmed response, median time to response was 1.3 months and median duration of response was 3.2 months.",Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18454159/),month,3.2,28244,DB00188,Bortezomib
,18454159,response rate,"At the MTD, response rate was 38%.",Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18454159/),%,38,28245,DB00188,Bortezomib
,32380027,entrapment efficiency,"The particle size of BTZ-PEG-PAMAM was 188.6 ± 4.17 nm, with entrapment efficiency of 78.61 ± 2.91% and drug loading of 39.30 ± 1.98%.",PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380027/),%,78.61,36629,DB00188,Bortezomib
,32380027,drug loading,"The particle size of BTZ-PEG-PAMAM was 188.6 ± 4.17 nm, with entrapment efficiency of 78.61 ± 2.91% and drug loading of 39.30 ± 1.98%.",PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380027/),%,39.30,36630,DB00188,Bortezomib
,32380027,IC50,"A comparative colorimetric MTT assay against A549 and MCF-7 cancer cells resulted in maximum efficacy from BTZ-PEG-PAMAM with IC50 value 333.14 ± 15.42 and 152.60 ± 24.56 nM, respectively.",PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380027/),nM,333.14,36631,DB00188,Bortezomib
,32380027,IC50,"A comparative colorimetric MTT assay against A549 and MCF-7 cancer cells resulted in maximum efficacy from BTZ-PEG-PAMAM with IC50 value 333.14 ± 15.42 and 152.60 ± 24.56 nM, respectively.",PEGylated Dendrimer Mediated Delivery of Bortezomib: Drug Conjugation versus Encapsulation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32380027/),nM,152.60,36632,DB00188,Bortezomib
,24019544,Overall response rate (ORR),Overall response rate (ORR) was 73.3% in the expansion phase and 52.9% at the escalation phase MTD.,Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24019544/),%,73.3,36829,DB00188,Bortezomib
,24019544,Overall response rate (ORR),Overall response rate (ORR) was 73.3% in the expansion phase and 52.9% at the escalation phase MTD.,Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24019544/),%,52.9,36830,DB00188,Bortezomib
,28341300,overall response rate,"The overall response rate in patients with measurable disease (n=21) was 19% (1 complete, 3 partial).",A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28341300/),%,19,47023,DB00188,Bortezomib
,25011071,half-life,The half-life of bortezomib in the blood was 23days.,Blood distribution of bortezomib and its kinetics in multiple myeloma patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25011071/),d,23,50664,DB00188,Bortezomib
,23018466,area under the plasma concentration-time curve from time zero to the last quantifiable timepoint (AUC(last)),Bortezomib systemic exposure was equivalent with subcutaneous versus intravenous administration in MMY-3021 [mean area under the plasma concentration-time curve from time zero to the last quantifiable timepoint (AUC(last)): 155 vs.,"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),,155,51441,DB00188,Bortezomib
,23018466,AUC(last),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),[h·ng] / [ml],195,51442,DB00188,Bortezomib
,23018466,AUC(last),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),[h·ng] / [ml],241,51443,DB00188,Bortezomib
,23018466,maximum (peak) plasma drug concentration (C(max)),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),[ng] / [ml],20.4,51444,DB00188,Bortezomib
,23018466,maximum (peak) plasma drug concentration (C(max)),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),[ng] / [ml],223,51445,DB00188,Bortezomib
,23018466,maximum (peak) plasma drug concentration (C(max)),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),[ng] / [ml],22.5,51446,DB00188,Bortezomib
,23018466,maximum (peak) plasma drug concentration (C(max)),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),[ng] / [ml],162,51447,DB00188,Bortezomib
,23018466,time to C(max) (t(max)),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),min,30,51448,DB00188,Bortezomib
,23018466,time to C(max) (t(max)),"151 ng·h/mL; geometric mean ratio 0.992 (90 % CI 80.18, 122.80)] and comparable in CAN-1004 (mean AUC(last): 195 vs. 241 ng·h/mL); maximum (peak) plasma drug concentration (C(max)) was lower with subcutaneous administration in both MMY-3021 (mean 20.4 vs. 223 ng/mL) and CAN-1004 (mean 22.5 vs. 162 ng/mL), and time to C(max) (t(max)) was longer with subcutaneous administration in both studies (median 30 vs. 2 min).","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),min,2,51449,DB00188,Bortezomib
,23018466,maximum effect (E(max)),"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%,63.7,51450,DB00188,Bortezomib
,23018466,maximum effect (E(max)),"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%,69.3,51451,DB00188,Bortezomib
,23018466,maximum effect (E(max)),"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%,57.0,51452,DB00188,Bortezomib
,23018466,maximum effect (E(max)),"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%,68.8,51453,DB00188,Bortezomib
,23018466,area under the effect-time curve from time zero to 72 h,"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%·h,"1,714",51454,DB00188,Bortezomib
,23018466,area under the effect-time curve from time zero to 72 h,"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%·h,"1,383",51455,DB00188,Bortezomib
,23018466,area under the effect-time curve from time zero to 72 h,"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%·h,"1,619",51456,DB00188,Bortezomib
,23018466,area under the effect-time curve from time zero to 72 h,"Blood 20S proteasome inhibition pharmacodynamic parameters were also similar with subcutaneous versus intravenous bortezomib: mean maximum effect (E(max)) was 63.7 versus 69.3 % in MMY-3021 and 57.0 versus 68.8 % in CAN-1004, and mean area under the effect-time curve from time zero to 72 h was 1,714 versus 1,383 %·h in MMY-3021 and 1,619 versus 1,283 %·h in CAN-1004.","Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),%·h,"1,283",51457,DB00188,Bortezomib
,23018466,Time to E(max),Time to E(max) was longer with subcutaneous administration in MMY-3021 (median 120 vs. 5 min) and CAN-1004 (median 120 vs. 3 min).,"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),min,120,51458,DB00188,Bortezomib
,23018466,Time to E(max),Time to E(max) was longer with subcutaneous administration in MMY-3021 (median 120 vs. 5 min) and CAN-1004 (median 120 vs. 3 min).,"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),min,5,51459,DB00188,Bortezomib
,23018466,Time to E(max),Time to E(max) was longer with subcutaneous administration in MMY-3021 (median 120 vs. 5 min) and CAN-1004 (median 120 vs. 3 min).,"Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23018466/),min,3,51460,DB00188,Bortezomib
,22087865,AUC from 0 to 72 hours (AUC(72h)),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],223,75193,DB00188,Bortezomib
,22087865,AUC from 0 to 72 hours (AUC(72h)),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],123,75194,DB00188,Bortezomib
,22087865,AUC(72h),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],179,75195,DB00188,Bortezomib
,22087865,AUC(72h),"Rifampicin reduced the mean AUC from 0 to 72 hours (AUC(72h)) of bortezomib by approximately 45% (223 ng · h/mL in cycle 2 vs 123 ng · h/mL in cycle 3), while dexamethasone had no effect (mean AUC(72h): 179 ng · h/mL in cycle 2 vs 170 ng · h/mL in cycle 3).","Effect of cytochrome P450 3A4 inducers on the pharmacokinetic, pharmacodynamic and safety profiles of bortezomib in patients with multiple myeloma or non-Hodgkin's lymphoma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22087865/),[h·ng] / [ml],170,75196,DB00188,Bortezomib
,27287072,time to progression,"The median time to progression (9 patients censored) was 4.8 months, and the median response duration (4 patients censored) was 7.2 months.","Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27287072/),month,4.8,77861,DB00188,Bortezomib
,27287072,response duration,"The median time to progression (9 patients censored) was 4.8 months, and the median response duration (4 patients censored) was 7.2 months.","Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27287072/),month,7.2,77862,DB00188,Bortezomib
,30058108,overall response rate,"The overall response rate was 83.3% (95% confidence interval, 43.6-97.0).",Weekly carfilzomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma: A phase 1 and PK/PD trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30058108/),%,83.3,80520,DB00188,Bortezomib
,21447728,MTD,The MTD was established as 1.3 mg/m(2) for bortezomib and 30 mg/m(2) for alvocidib (both the 30-minute bolus and 4-hour infusions).,Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447728/),[mg] / [m(2],1.3,81687,DB00188,Bortezomib
,21447728,MTD,The MTD was established as 1.3 mg/m(2) for bortezomib and 30 mg/m(2) for alvocidib (both the 30-minute bolus and 4-hour infusions).,Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447728/),[mg] / [m(2],30,81688,DB00188,Bortezomib
,21447728,overall response rate,Two complete responses (CR; 12%) and five partial responses (PR; 31%) were observed at the MTD (overall response rate = 44%).,Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21447728/),%,44,81689,DB00188,Bortezomib
,15570082,inhibition,The average inhibition 1 hour after drug administration on day 1 was 67.2% +/- 7.6% at the 1.2 mg/m2/dose and 76.5% +/- 3.3% at the 1.6 mg/m2/dose.,Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570082/),%,67.2,125461,DB00188,Bortezomib
,15570082,inhibition,The average inhibition 1 hour after drug administration on day 1 was 67.2% +/- 7.6% at the 1.2 mg/m2/dose and 76.5% +/- 3.3% at the 1.6 mg/m2/dose.,Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570082/),%,76.5,125462,DB00188,Bortezomib
<,27769033,IC50,"Compared with Bortezomib, I-14 showed higher potency against the chymotrypsin-like activity of human 20S proteasome (IC50 < 1 pM), similar potency against four different cancer cell lines (IC50 < 10 nM), and better pharmacokinetic profile.",Urea-containing peptide boronic acids as potent proteasome inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27769033/),pM,1,128180,DB00188,Bortezomib
<,27769033,IC50,"Compared with Bortezomib, I-14 showed higher potency against the chymotrypsin-like activity of human 20S proteasome (IC50 < 1 pM), similar potency against four different cancer cell lines (IC50 < 10 nM), and better pharmacokinetic profile.",Urea-containing peptide boronic acids as potent proteasome inhibitors. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27769033/),nM,10,128181,DB00188,Bortezomib
,24904120,MTD,The MTD was determined to be 2.97 mg/m(2).,Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24904120/),[mg] / [m(2],2.97,128549,DB00188,Bortezomib
,24904120,terminal half-life,"Pharmacokinetic studies suggested a long terminal half-life of 3.6 to 11.3 days, supporting once-weekly dosing.",Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24904120/),d,3.6 to 11.3,128550,DB00188,Bortezomib
,33279887,overall response rate,The overall response rate (CR + nCR + partial response) was 80.6%.,"Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33279887/),%,80.6,130766,DB00188,Bortezomib
,33279887,P,"The median PFS, duration of response, time to response, and time to progression were 15.3, 22.7, 1.4, and 15.3 months, respectively.","Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33279887/),month,15.3,130767,DB00188,Bortezomib
,33279887,time to response,"The median PFS, duration of response, time to response, and time to progression were 15.3, 22.7, 1.4, and 15.3 months, respectively.","Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33279887/),month,22.7,130768,DB00188,Bortezomib
,33279887,time to response,"The median PFS, duration of response, time to response, and time to progression were 15.3, 22.7, 1.4, and 15.3 months, respectively.","Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33279887/),month,1.4,130769,DB00188,Bortezomib
,33279887,time to progression,"The median PFS, duration of response, time to response, and time to progression were 15.3, 22.7, 1.4, and 15.3 months, respectively.","Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33279887/),month,15.3,130770,DB00188,Bortezomib
,25294016,overall response rate,"For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103).","A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294016/),%,55,132664,DB00188,Bortezomib
,25294016,overall response rate,"For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103).","A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294016/),%,47,132665,DB00188,Bortezomib
,25294016,complete response rate,"For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103).","A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294016/),%,11,132666,DB00188,Bortezomib
,25294016,complete response rate,"For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103).","A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294016/),%,7,132667,DB00188,Bortezomib
,25294016,overall survival (OS),"For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103).","A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294016/),month,30.8,132668,DB00188,Bortezomib
,25294016,overall survival (OS),"For the 281 randomized patients, median PFS for S + B and plc + B was 8.0 and 7.6 months (HR 0.869, P = 0.345), overall response rate was 55 versus 47% (P = 0.213), complete response rate was 11 versus 7%, and median overall survival (OS) was 30.8 versus 36.8 months (HR 1.353, P = 0.103).","A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25294016/),month,36.8,132669,DB00188,Bortezomib
,25939707,Bioavailability,Bioavailability was 21.4 %.,Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939707/),%,21.4,139766,DB00188,Bortezomib
,25939707,clearance,Median clearance was 33.1 L/h.,Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939707/),[l] / [h],33.1,139767,DB00188,Bortezomib
,25939707,area under the curve (AUC),"For Caucasian patients of median age 61 years, area under the curve (AUC) decreased from 104 to 88 ng · h/mL as body surface area (BSA) increased from the first to third quartiles, 1.8 to 2.1 m(2).",Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939707/),[h·ng] / [ml],104,139768,DB00188,Bortezomib
,25939707,AUC,"For Caucasian patients of median BSA 1.9 m(2), AUC decreased from 102 to 95 ng · h/mL as age increased from the first to third quartiles, 51 to 70 years.",Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939707/),[h·ng] / [ml],102,139769,DB00188,Bortezomib
,25939707,AUC,"For Caucasian patients of median BSA 1.9 m(2), AUC decreased from 102 to 95 ng · h/mL as age increased from the first to third quartiles, 51 to 70 years.",Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939707/),[h·ng] / [ml],95,139770,DB00188,Bortezomib
,25939707,AUC,"For patients of median BSA and median age, AUC ranged across the four race categories from 80 to 116 ng · h/mL.",Population pharmacokinetics of intravenous and oral panobinostat in patients with hematologic and solid tumors. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25939707/),[h·ng] / [ml],80 to 116,139771,DB00188,Bortezomib
,17332297,clearance,"Pharmacokinetic analysis at 1.3 mg/m(2) revealed a clearance of 11 mL/h/m(2), a central volume of distribution of 6.7 L/m(2), and a terminal half-life of 12.6 h.",A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332297/),[h·ml] / [m(2],11,140734,DB00188,Bortezomib
,17332297,central volume of distribution,"Pharmacokinetic analysis at 1.3 mg/m(2) revealed a clearance of 11 mL/h/m(2), a central volume of distribution of 6.7 L/m(2), and a terminal half-life of 12.6 h.",A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332297/),[l] / [m(2],6.7,140735,DB00188,Bortezomib
,17332297,terminal half-life,"Pharmacokinetic analysis at 1.3 mg/m(2) revealed a clearance of 11 mL/h/m(2), a central volume of distribution of 6.7 L/m(2), and a terminal half-life of 12.6 h.",A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17332297/),h,12.6,140736,DB00188,Bortezomib
less,15688598,plasma distribution half-life,"Bortezomib is rapidly distributed into tissues after administration of a single dose, with an initial plasma distribution half-life of less than 10 minutes, followed by a terminal elimination half-life of more than 40 hours.","Pharmacology, pharmacokinetics, and practical applications of bortezomib. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15688598/),min,10,141608,DB00188,Bortezomib
more,15688598,terminal elimination half-life,"Bortezomib is rapidly distributed into tissues after administration of a single dose, with an initial plasma distribution half-life of less than 10 minutes, followed by a terminal elimination half-life of more than 40 hours.","Pharmacology, pharmacokinetics, and practical applications of bortezomib. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15688598/),h,40,141609,DB00188,Bortezomib
,15626743,MTD,"The MTD based on cycle 1 was 1.50 and 30 mg/m2 of bortezomib and PegLD, respectively.",Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626743/),[mg] / [m2],1.50,144532,DB00188,Bortezomib
,15626743,MTD,"The MTD based on cycle 1 was 1.50 and 30 mg/m2 of bortezomib and PegLD, respectively.",Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15626743/),[mg] / [m2],30,144533,DB00188,Bortezomib
,28430745,overall response rate,A total of 35 patients with complete data were analyzed and the overall response rate was 91.4%.,Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28430745/),%,91.4,151188,DB00188,Bortezomib
,19385713,maximum plasma concentration,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[ng] / [ml],120,156123,DB00188,Bortezomib
,19385713,maximum plasma concentration,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[ng] / [ml],123,156124,DB00188,Bortezomib
,19385713,area under the plasma concentration-time curve from 0 to 72 hours,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[h·ng] / [ml],129,156125,DB00188,Bortezomib
,19385713,area under the plasma concentration-time curve from 0 to 72 hours,Bortezomib pharmacokinetic parameters were similar when bortezomib was administered alone or with omeprazole (maximum plasma concentration 120 vs 123 ng/mL; area under the plasma concentration-time curve from 0 to 72 hours 129 vs 135 ng . h/mL).,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),[h·ng] / [ml],135,156126,DB00188,Bortezomib
,19385713,area under the percent inhibition-time curve over 72 hours,The pharmacodynamic parameters were also similar (maximum effect 85.8% vs 93.7%; area under the percent inhibition-time curve over 72 hours 4052 vs 3910 % x h); the differences were not statistically significant.,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),%·h,4052,156127,DB00188,Bortezomib
,19385713,area under the percent inhibition-time curve over 72 hours,The pharmacodynamic parameters were also similar (maximum effect 85.8% vs 93.7%; area under the percent inhibition-time curve over 72 hours 4052 vs 3910 % x h); the differences were not statistically significant.,"Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19385713/),%·h,3910,156128,DB00188,Bortezomib
,27164062,area under the concentration-time curve,"BU was administered i.v. daily for 4 days to achieve a target area under the concentration-time curve total of 20,000 mM·min based on pharmacokinetic analysis after the first dose.","Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27164062/),mM·min,"20,000",156740,DB00188,Bortezomib
,28667459,maximum plasma concentration (C max),"Pooled data of multiple-dose studies show that an oral dose of panobinostat 20 mg resulted in a maximum plasma concentration (C max) of 21.6 ng/mL approximately 1 h after administration, while doses between 10 and 30 mg resulted in dose proportional plasma levels.",Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667459/),[ng] / [ml],21.6,163568,DB00188,Bortezomib
,28667459,absolute bioavailability,"The absolute bioavailability of panobinostat is 21.4%, and it is moderately bound to plasma proteins.",Clinical Pharmacokinetics and Pharmacodynamics of Panobinostat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28667459/),%,21.4,163569,DB00188,Bortezomib
,16763792,AUC,"The maximum tolerated dose and the recommended doses for future phase II trials are bortezomib 1.2 mg/m2, paclitaxel 135 mg/m2 and carboplatin AUC = 6 for schedule A and bortezomib 1.2 mg/m2, paclitaxel 175 mg/m2 and carboplatin AUC = 6 for schedule B. Six (21.4%) partial responses (PR) were seen with schedule B.","A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16763792/),,6,170052,DB00188,Bortezomib
,21400028,tumor growth inhibition (TGI),Bortezomib dosed twice-weekly at 0.8 mg/kg IV demonstrated tumor growth inhibition (TGI) of 53.9-58.9%.,"Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21400028/),%,53.9-58.9,187391,DB00188,Bortezomib
,27350068,overall response rate,"The overall response rate was 56.3%, suggesting that the combined treatment was effective.",Dose-escalation study of tabalumab with bortezomib and dexamethasone in Japanese patients with multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27350068/),%,56.3,188340,DB00188,Bortezomib
,34341512,oral bioavailability (F%,Preclinical pharmacokinetic study showed bisthianostat was quickly absorbed with moderate oral bioavailability (F% = 16.9%-35.5%).,"Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341512/),%,16.9,192557,DB00188,Bortezomib
,34341512,oral bioavailability (F%,Preclinical pharmacokinetic study showed bisthianostat was quickly absorbed with moderate oral bioavailability (F% = 16.9%-35.5%).,"Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341512/),%,35.5,192558,DB00188,Bortezomib
,34341512,Vss,Bisthianostat tended to distribute in blood with Vss value of 0.31 L/kg.,"Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34341512/),[l] / [kg],0.31,192559,DB00188,Bortezomib
,21850464,MTDs,"The MTDs for the combination of bortezomib and temozolomide in patients not taking HEIAs are 1.3 and 200 mg/m(2), respectively.",A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850464/),[mg] / [m(2],1.3,197125,DB00188,Bortezomib
,21850464,MTDs,"The MTDs for the combination of bortezomib and temozolomide in patients not taking HEIAs are 1.3 and 200 mg/m(2), respectively.",A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21850464/),[mg] / [m(2],200,197126,DB00188,Bortezomib
,31401767,maximum tolerated dose,The maximum tolerated dose was defined as 1.3 mg/m2.,Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401767/),[mg] / [m2],1.3,203417,DB00188,Bortezomib
,31401767,maximum plasma concentration,"The mean maximum plasma concentration and area under the concentration-time curve was 74.0 ng/mL and 73.9 ng h/mL, respectively.",Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401767/),[ng] / [ml],74.0,203418,DB00188,Bortezomib
,31401767,area under the concentration-time curve,"The mean maximum plasma concentration and area under the concentration-time curve was 74.0 ng/mL and 73.9 ng h/mL, respectively.",Bortezomib-containing therapy in Japanese children with relapsed acute lymphoblastic leukemia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31401767/),[h·ng] / [ml],73.9,203419,DB00188,Bortezomib
,29260507,TTR,The median TTR was 0.9 months.,Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29260507/),month,0.9,207042,DB00188,Bortezomib
,32097684,IC50,"IC50 value of these PNPs was 56.06 ± 0.12 nM, which was approximately two folds less than BTZ (p < 0.0001).",Biotinylated HPMA centered polymeric nanoparticles for Bortezomib delivery. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32097684/),nM,56.06,207798,DB00188,Bortezomib
,18316568,total body clearance,"Pharmacokinetic studies revealed that the total body clearance of bortezomib decreased significantly (P < 0.01, N = 26) between the first (mean +/- SD, 41.9 +/- 17.1 L/h/m(2)) and third (18.4 +/- 7.0 L/h/m(2)) doses.",Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316568/),[h·l] / [m(2],41.9,215866,DB00188,Bortezomib
,18316568,total body clearance,"Pharmacokinetic studies revealed that the total body clearance of bortezomib decreased significantly (P < 0.01, N = 26) between the first (mean +/- SD, 41.9 +/- 17.1 L/h/m(2)) and third (18.4 +/- 7.0 L/h/m(2)) doses.",Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18316568/),[h·l] / [m(2],18.4,215867,DB00188,Bortezomib
,31313068,maximal inhibitory effect,The maximal inhibitory effect was 0.696 pmol AMC/s/mg protein (95% confidence interval 0.664-0.728) after administration.,A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31313068/),[aMc·pM] / [mg·s],0.696,221706,DB00188,Bortezomib
,26494130,area under curve from 0 to 24 h (AUC0-24),"At maximum tolerated dose (MTD), the geometric mean of panobinostat area under curve from 0 to 24 h (AUC0-24) was 47.5 ng h/mL (77 % CV), and maximum plasma concentration (Cmax) was 8.1 ng/mL (90 % CV).",Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26494130/),[h·ng] / [ml],47.5,226283,DB00188,Bortezomib
,26494130,maximum plasma concentration (Cmax),"At maximum tolerated dose (MTD), the geometric mean of panobinostat area under curve from 0 to 24 h (AUC0-24) was 47.5 ng h/mL (77 % CV), and maximum plasma concentration (Cmax) was 8.1 ng/mL (90 % CV).",Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26494130/),[ng] / [ml],8.1,226284,DB00188,Bortezomib
,17970782,overall response rate,"The overall response rate was 30% (95% confidence interval, 16-49%).",Phase I and II pharmacokinetic and pharmacodynamic study of the proteasome inhibitor bortezomib in Japanese patients with relapsed or refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17970782/),%,30,231619,DB00188,Bortezomib
,25139216,total area under the concentration-time curve (AUC),"Because a safe Bu exposure was unknown in patients receiving this combination, Bu was initially targeted to a total area under the concentration-time curve (AUC) of 20,000 μM × minute.",Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25139216/),min·μM,"20,000",231946,DB00188,Bortezomib
,25139216,time from first to second transplantation,"Median time from first to second transplantation was 28.0 months (range, 12 to 119).",Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25139216/),month,28.0,231947,DB00188,Bortezomib
,25139216,progression-free survival,"Median progression-free survival was 191 days, whereas median overall survival was not reached during the study period.",Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25139216/),d,191,231948,DB00188,Bortezomib
,29076150,overall response rate,"The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively.","A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076150/),%,53,241002,DB00188,Bortezomib
,29076150,clinical benefit rate,"The overall response rate and clinical benefit rate was 53% (19/36) and 64% (23/36), respectively.","A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29076150/),%,64,241003,DB00188,Bortezomib
,24920586,maximum tolerated dose,"The maximum tolerated dose was 2.0 mg/m(2), which 40 patients received in 4 expansion cohorts.","Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),[mg] / [m(2],2.0,242784,DB00188,Bortezomib
,24920586,terminal half-life,The terminal half-life of ixazomib was 3.3 to 7.4 days; plasma exposure increased proportionally with dose (0.48-2.23 mg/m(2)).,"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24920586/),d,3.3 to 7.4,242785,DB00188,Bortezomib
,23364621,overall response rate,"Although nearly 50% of patients were refractory to both bortezomib and lenalidomide, end of study partial response or better (overall response rate) was 25.5% with 7.9 months median duration of response.",Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23364621/),,25.5,248829,DB00188,Bortezomib
,23782711,disease control rate,"In the efficacy population (n = 187), the disease control rate (at least stable disease) was 94.7%, and the overall response rate (at least partial response) was 47.6%.","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),%,94.,250339,DB00188,Bortezomib
,23782711,overall response rate,"In the efficacy population (n = 187), the disease control rate (at least stable disease) was 94.7%, and the overall response rate (at least partial response) was 47.6%.","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),%,47.6,250340,DB00188,Bortezomib
,23782711,response duration,"After a median study follow-up of 15.2 months, the median response duration was 8.8 months (range, 0.4-18.8 months) and median progression-free survival was 8.3 months (95% CI 6.5-9.8).","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),month,8.8,250341,DB00188,Bortezomib
,23782711,progression-free survival,"After a median study follow-up of 15.2 months, the median response duration was 8.8 months (range, 0.4-18.8 months) and median progression-free survival was 8.3 months (95% CI 6.5-9.8).","A multicenter, open-label, phase 2 study of lenalidomide plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma: the MM-021 trial. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782711/),month,8.3,250342,DB00188,Bortezomib
,28684379,total area under the curve (AUC),"Bu dosing was adjusted to target a total area under the curve (AUC) of 20,000 μM × min.",Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684379/),min·μM,"20,000",258488,DB00188,Bortezomib
,28684379,total AUC,"PK testing resulted in 86% of patients achieving an estimated total AUC of 20,000 ± 2500 μM × min.",Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684379/),min·μM,"20,000",258489,DB00188,Bortezomib
,28684379,overall response rate (ORR),"The overall response rate (ORR) at day +100 after ASCT was 100% in the evaluable patients, with 11% of patients achieving a complete response.",Pharmacokinetics-directed Intravenous Busulfan Combined With High-dose Melphalan and Bortezomib as a Conditioning Regimen for Patients With Multiple Myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28684379/),%,100,258490,DB00188,Bortezomib
,32874573,plasma concentrations,"Patient 1 had plasma concentrations of ixazomib averaging 26.2, 21.8 and 15.3 ng/ml at incision, tumor sampling and closure, respectively.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],26.2,263413,DB00188,Bortezomib
,32874573,plasma concentrations,"Patient 1 had plasma concentrations of ixazomib averaging 26.2, 21.8 and 15.3 ng/ml at incision, tumor sampling and closure, respectively.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],21.8,263414,DB00188,Bortezomib
,32874573,plasma concentrations,"Patient 1 had plasma concentrations of ixazomib averaging 26.2, 21.8 and 15.3 ng/ml at incision, tumor sampling and closure, respectively.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],15.3,263415,DB00188,Bortezomib
,32874573,brain tumor tissue concentration,The brain tumor tissue concentration was 7.88 ng/g.,A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [g],7.88,263416,DB00188,Bortezomib
,32874573,plasma concentration interval,"Patient 3 had plasma concentration interval measurements of 25.6, 36.2 and 28.7 ng/ml.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],25.6,263417,DB00188,Bortezomib
,32874573,plasma concentration interval,"Patient 3 had plasma concentration interval measurements of 25.6, 36.2 and 28.7 ng/ml.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],36.2,263418,DB00188,Bortezomib
,32874573,plasma concentration interval,"Patient 3 had plasma concentration interval measurements of 25.6, 36.2 and 28.7 ng/ml.",A phase 0 analysis of ixazomib in patients with glioblastoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32874573/),[ng] / [ml],28.7,263419,DB00188,Bortezomib
,20306195,Plasma clearance,"Plasma clearance decreased with repeat dosing (102-112 L/h for first dose; 15-32 L/h following repeat dosing), with associated increases in systemic exposure and terminal half-life.",Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306195/),[l] / [h],102-112,266292,DB00188,Bortezomib
,20306195,Plasma clearance,"Plasma clearance decreased with repeat dosing (102-112 L/h for first dose; 15-32 L/h following repeat dosing), with associated increases in systemic exposure and terminal half-life.",Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306195/),[l] / [h],15-32,266293,DB00188,Bortezomib
,20306195,maximum inhibition,Blood 20S proteasome inhibition profiles were similar between groups with mean maximum inhibition ranging from 70 to 84% and decreasing toward baseline over the dosing interval.,Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306195/),%,70 to 84,266294,DB00188,Bortezomib
,20306195,Response rate,"Response rate (all 42 patients) was 50%, including 7% complete responses.",Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20306195/),%,50,266295,DB00188,Bortezomib
,19671864,Overall response rate,"Overall response rate was 42%, including three partial responses among nine bortezomib refractory patients.",Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19671864/),%,42,267419,DB00188,Bortezomib
,28092421,overall response rate,The overall response rate was 88.5%.,"Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28092421/),%,88.5,271881,DB00188,Bortezomib
,28873084,objective response rate,"In the efficacy evaluable phase I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4-50.9%), clinical benefit rate 51.9% (40.4-63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months.","A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28873084/),%,39.2,272242,DB00188,Bortezomib
,28873084,clinical benefit rate,"In the efficacy evaluable phase I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4-50.9%), clinical benefit rate 51.9% (40.4-63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months.","A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28873084/),%,51.9,272243,DB00188,Bortezomib
,28873084,progression-free survival,"In the efficacy evaluable phase I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4-50.9%), clinical benefit rate 51.9% (40.4-63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months.","A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28873084/),month,6.7,272244,DB00188,Bortezomib
,28873084,duration of response,"In the efficacy evaluable phase I/II population treated at the RP2D (n=79), the objective response rate was 39.2% (95% confidence interval: 28.4-50.9%), clinical benefit rate 51.9% (40.4-63.3%), median progression-free survival 6.7 (5.9-not reached (NR)) months, and median duration of response 5.5 (4.9-NR) months.","A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28873084/),,5.5,272245,DB00188,Bortezomib
